RYCMX | RYVYX | RYCMX / RYVYX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 24 years | 25 years | - |
Gain YTD | 18.169 | 48.284 | 38% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 2500 | 100% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 8.15M | 1.53B | 1% |
Annual Yield % from dividends | 0.27 | 0.00 | - |
Returns for 1 year | 22.10 | 49.61 | 45% |
Returns for 3 years | -1.99 | 34.60 | -6% |
Returns for 5 years | -25.86 | 221.62 | -12% |
Returns for 10 years | -8.85 | 735.01 | -1% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
NILIX | 13.81 | N/A | N/A |
Neuberger Berman International Sel I | |||
BGGKX | 28.74 | N/A | N/A |
Baillie Gifford US Equity Growth K | |||
SHSKX | 68.70 | -0.01 | -0.01% |
BlackRock Health Sciences Opps K | |||
PNRAX | 54.30 | -0.30 | -0.55% |
Putnam Research A | |||
PMDIX | 19.28 | -0.24 | -1.23% |
Principal Small-MidCap Dividend Inc Inst |